Related Experiment Video
Updated: Jun 20, 2026

Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
New treatment with human atrial natriuretic peptide for postoperative myonephropathic metabolic syndrome
Akira Sezai1, Mitsumasa Hata, Tesuya Niino
1The Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan. asezai@med.nihon-u.ac.jp
Abstract:
A 49-year-old man had sudden chest pain and paralysis of the lower right limb. An acute aortic dissection was diagnosed in a computed tomography scan and the patient underwent an emergency operation. After the operation, myonephropathic metabolic syndrome developed, and human atrial natriuretic peptide was administered for 11 days until the volume of daily urine output reached at least 10,000 mL, which would facilitate limb salvage and the preservation of life without hemodialysis. This report documents that postoperative myonephropathic metabolic syndrome improved due to the strong diuretic action of human atrial natriuretic peptide without hemodialysis.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cardiomyopathy V: Interprofessional Care
